Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Clinical correlates of health-related quality of life among opioid-dependent patients.

Heslin KC, Stein JA, Heinzerling KG, Pan D, Magladry C, Hays RD.

Qual Life Res. 2011 Oct;20(8):1205-13. doi: 10.1007/s11136-011-9858-y. Epub 2011 Feb 17.

2.

Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.

Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L, Egan JE, Botsko M, Acosta A, Gourevitch MN, Hersh D, Hsu J, Boverman J, Altice FL; BHIVES Collaborative..

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S39-45. doi: 10.1097/QAI.0b013e318209754c.

3.

Short term health-related quality of life improvement during opioid agonist treatment.

Nosyk B, Bray JW, Wittenberg E, Aden B, Eggman AA, Weiss RD, Potter J, Ang A, Hser YI, Ling W, Schackman BR.

Drug Alcohol Depend. 2015 Dec 1;157:121-8. doi: 10.1016/j.drugalcdep.2015.10.009. Epub 2015 Oct 25.

4.

Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.

Northrup TF, Stotts AL, Green C, Potter JS, Marino EN, Walker R, Weiss RD, Trivedi M.

Addict Behav. 2015 Feb;41:20-8. doi: 10.1016/j.addbeh.2014.09.021. Epub 2014 Sep 28.

5.

Health-related quality of life changes associated with buprenorphine treatment for opioid dependence.

Raisch DW, Campbell HM, Garnand DA, Jones MA, Sather MR, Naik R, Ling W.

Qual Life Res. 2012 Sep;21(7):1177-83. doi: 10.1007/s11136-011-0027-0. Epub 2011 Oct 11.

6.

Comparison of behavioral treatment conditions in buprenorphine maintenance.

Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J.

Addiction. 2013 Oct;108(10):1788-98. doi: 10.1111/add.12266. Epub 2013 Jul 12.

7.

Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.

Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG.

Clin Drug Investig. 2010;30 Suppl 1:21-6. doi: 10.2165/11536010-000000000-00000.

PMID:
20450242
8.

"Should I stay or should I go?" Coming off methadone and buprenorphine treatment.

Winstock AR, Lintzeris N, Lea T.

Int J Drug Policy. 2011 Jan;22(1):77-81. doi: 10.1016/j.drugpo.2010.08.001. Epub 2010 Oct 16.

PMID:
20956077
9.

Buprenorphine for the management of opioid withdrawal.

Gowing L, Ali R, White J.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002025. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD002025.

PMID:
15495026
10.

Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Ziedonis DM, Amass L, Steinberg M, Woody G, Krejci J, Annon JJ, Cohen AJ, Waite-O'Brien N, Stine SM, McCarty D, Reid MS, Brown LS Jr, Maslansky R, Winhusen T, Babcock D, Brigham G, Muir J, Orr D, Buchan BJ, Horton T, Ling W.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):28-36. doi: 10.1016/j.drugalcdep.2008.06.016. Epub 2008 Sep 20.

11.

Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users.

Lubman D, Koutsogiannis Z, Kronborg I.

Drug Alcohol Rev. 2003 Dec;22(4):433-6.

PMID:
14660133
12.

Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.

Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, Brooklyn J.

Arch Gen Psychiatry. 2005 Oct;62(10):1157-64.

PMID:
16203961
13.

Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation.

Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE.

Psychopharmacology (Berl). 2008 Jun;198(2):149-58. doi: 10.1007/s00213-008-1105-z. Epub 2008 Mar 9.

PMID:
18327673
14.

Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance treatment trial.

Reimer J, Verthein U, Karow A, Schäfer I, Naber D, Haasen C.

Addiction. 2011 Sep;106(9):1647-55. doi: 10.1111/j.1360-0443.2011.03463.x. Epub 2011 Jul 22.

PMID:
21489005
15.

Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.

Chawla JM, Pal H, Lal R, Jain R, Schooler N, Balhara YP.

J Opioid Manag. 2013 Jan-Feb;9(1):35-41. doi: 10.5055/jom.2013.0145.

PMID:
23709302
16.
17.

Buprenorphine for the management of opioid withdrawal.

Gowing L, Ali R, White J.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD002025. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD002025.

PMID:
16625553
18.

Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Montesano F, Zaccone D, Battaglia E, Genco F, Mellace V.

Clin Drug Investig. 2010;30 Suppl 1:13-9. doi: 10.2165/11536040-000000000-00000.

PMID:
20450241
19.

Compliance with buprenorphine medication-assisted treatment and relapse to opioid use.

Tkacz J, Severt J, Cacciola J, Ruetsch C.

Am J Addict. 2012 Jan-Feb;21(1):55-62. doi: 10.1111/j.1521-0391.2011.00186.x. Epub 2011 Nov 18.

PMID:
22211347
20.

Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.

Strain EC, Stitzer ML, Liebson IA, Bigelow GE.

J Clin Psychopharmacol. 1996 Feb;16(1):58-67.

PMID:
8834420

Supplemental Content

Support Center